Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 555Triple Negative Breast Neoplasms 94Inflammatory Breast Neoplasms 38Breast Neoplasms, Male 31Neoplasm Metastasis 27Ovarian Neoplasms 25Carcinoma, Non-Small-Cell Lung 23Melanoma 21Pancreatic Neoplasms 14Neoplasms 14Colorectal Neoplasms 13Carcinoma, Renal Cell 12Stomach Neoplasms 11Multiple Myeloma 10Lung Neoplasms 10Carcinoma, Ovarian Epithelial 9Carcinoma, Hepatocellular 9Lymphoma, Non-Hodgkin 8Sarcoma 7Lymphoma, Follicular 7Lymphoma 7Carcinoma, Ductal, Breast 7Recurrence 6Neutropenia 6Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Leukemia, Myeloid, Acute 6Leukemia, Lymphocytic, Chronic, B-Cell 6

Interventions

lenvatinib 1camrelizumab 1apatinib 1Cyclophosphamide 1Albumin-Bound Paclitaxel 1ALT-803 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Triple Negative Breast Cancer × Cyclophosphamide × Breast × Clear all
NCT04927884 2024-06-12

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

ImmunityBio, Inc.

Phase 1/2 Terminated
3 enrolled 9 charts
Breast

Advanced Triple Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡